Informationen:
Fehler:
ID
43013
Beschreibung
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study; ODM derived from: https://clinicaltrials.gov/show/NCT01747746
Link
https://clinicaltrials.gov/show/NCT01747746
Stichworte
Versionen (2)
- 06.08.19 06.08.19 -
- 17.09.21 17.09.21 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
17. September 2021
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Atrial Fibrillation NCT01747746
Eligibility Atrial Fibrillation NCT01747746
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Atrial Fibrillation NCT01747746
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Atrial Fibrillation Requirement Electric Countershock | Atrial Fibrillation Duration Unknown
Item
patients with non-valvular atrial fibrillation requiring electrical cardioversion o atrial fibrillation of unknown duration
boolean
C0004238 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0013778 (UMLS CUI [1,3])
C0004238 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0439673 (UMLS CUI [2,3])
C1514873 (UMLS CUI [1,2])
C0013778 (UMLS CUI [1,3])
C0004238 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0439673 (UMLS CUI [2,3])
Patient need for Anticoagulation Therapy Extended | Status post Electric Countershock | Risk factors CHADS2 score
Item
patients requiring extended anticoagulation after cardioversion due to concomitant risk factors as defined by chads2 score ≥ 1
boolean
C0686904 (UMLS CUI [1,1])
C0003281 (UMLS CUI [1,2])
C0231448 (UMLS CUI [1,3])
C0231290 (UMLS CUI [2,1])
C0013778 (UMLS CUI [2,2])
C0035648 (UMLS CUI [3,1])
C2585876 (UMLS CUI [3,2])
C0003281 (UMLS CUI [1,2])
C0231448 (UMLS CUI [1,3])
C0231290 (UMLS CUI [2,1])
C0013778 (UMLS CUI [2,2])
C0035648 (UMLS CUI [3,1])
C2585876 (UMLS CUI [3,2])
Renal dysfunction | Creatinine clearance measurement
Item
significant renal dysfunction (crcl <15ml/min)
boolean
C3279454 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
C0373595 (UMLS CUI [2])
Liver Dysfunction Child-Pugh Classification
Item
significant hepatic dysfunction (childs-pugh class b or c)
boolean
C0086565 (UMLS CUI [1,1])
C4050412 (UMLS CUI [1,2])
C4050412 (UMLS CUI [1,2])
Blood Coagulation Disorder
Item
history of coagulopathy
boolean
C0005779 (UMLS CUI [1])
Hemorrhage
Item
active bleeding
boolean
C0019080 (UMLS CUI [1])
Hypersensitivity Rivaroxaban
Item
hypersensitivity to rivaroxaban
boolean
C0020517 (UMLS CUI [1,1])
C1739768 (UMLS CUI [1,2])
C1739768 (UMLS CUI [1,2])
Anticoagulants
Item
concomitant use of anticoagulants
boolean
C0003280 (UMLS CUI [1])
CYP3A4 Inhibitors Strong | CYP3A4 Inducers Strong | P-Glycoprotein Inhibitors Strong | P-Glycoprotein Inducers Strong
Item
concomitant use of potent cyp3a4/p-gp inhibitors or inducers
boolean
C3850053 (UMLS CUI [1,1])
C0442821 (UMLS CUI [1,2])
C3850041 (UMLS CUI [2,1])
C0442821 (UMLS CUI [2,2])
C3500483 (UMLS CUI [3,1])
C0442821 (UMLS CUI [3,2])
C3883353 (UMLS CUI [4,1])
C0442821 (UMLS CUI [4,2])
C0442821 (UMLS CUI [1,2])
C3850041 (UMLS CUI [2,1])
C0442821 (UMLS CUI [2,2])
C3500483 (UMLS CUI [3,1])
C0442821 (UMLS CUI [3,2])
C3883353 (UMLS CUI [4,1])
C0442821 (UMLS CUI [4,2])
Intervention Reason for Treatment Interruption
Item
interventions requiring interruption of therapy
boolean
C0184661 (UMLS CUI [1,1])
C3538832 (UMLS CUI [1,2])
C3538832 (UMLS CUI [1,2])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
Age
Item
age <18 y/o
boolean
C0001779 (UMLS CUI [1])
Gastrointestinal Hemorrhage
Item
history of gi bleed
boolean
C0017181 (UMLS CUI [1])